Comparison of efficacy and safety of salvage-line nivolumab monotherapy between 240 and 480 mg for advanced esophageal squamous cell carcinoma.

被引：0
|
作者：
Murashima, Yuko
Yamamoto, Shun
Hirose, Toshiharu
Kadono, Toru
Ikeda, Go
Ohara, Akihiro
Itoyama, Mai
Yokoyama, Kazuki
Honma, Yoshitaka
Ishiyama, Koshiro
Oguma, Junya
Daiko, Hiroyuki
Kato, Ken
机构：
[1] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Esophageal Surg, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
317
引用
下载
收藏
页码：317 / 317
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FUTURE ONCOLOGY, 2020, 16 (17) : 1189 - 1198
  • [22] The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma
    Xu, Weili
    Jiang, Youhua
    Wang, Changchun
    Wu, Jie
    Li, Jianqiang
    Hu, Yuqian
    Lu, Weishan
    Shen, Dijian
    Wang, Yinjie
    Chen, Qixun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma
    Liu, Guohui
    Wang, Yanbo
    Wang, Chunbo
    He, Yunlong
    Mingyan, E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (12) : 1423 - 1430
  • [24] Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma
    Habu, Takumi
    Bando, Hideaki
    Kumanishi, Ryosuke
    Ogata, Takatsugu
    Fujisawa, Takeshi
    Kumagai, Shogo
    Fujiwara, Hisashi
    Mishima, Saori
    Kotani, Daisuke
    Nakamura, Masaki
    Hojo, Hidehiro
    Yoda, Yusuke
    Koyama, Shohei
    Nishikawa, Hiroyoshi
    Yano, Tomonori
    Fujita, Takeo
    Kadowaki, Shigenori
    Muro, Kei
    Kinoshita, Takahiro
    Kojima, Takashi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [25] Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
    Wu, Zhigang
    Zheng, Qiang
    Chen, Haiquan
    Xiang, Jiaqing
    Hu, Hong
    Li, Hang
    Pan, Yunjian
    Peng, Yizhou
    Yao, Xingxin
    Liu, Pengcheng
    Sun, Yihua
    Li, Bin
    Zhang, Yawei
    JOURNAL OF THORACIC DISEASE, 2021, 13 (06) : 3518 - 3528
  • [26] Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review
    Xu, Jianming
    Bai, Yuxian
    Li, Enxiao
    Xu, Nong
    Shi, Danfeng
    Qian, Jing
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (09) : 981 - 998
  • [27] Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.
    Yoshinami, Yuri
    Yamamoto, Shun
    Kadono, Toru
    Hirose, Toshiharu
    Ikeda, Go
    Ohara, Akihiro
    Itoyama, Mai
    Yokoyama, Kazuki
    Honma, Yoshitaka
    Ishiyama, Koshiro
    Oguma, Junya
    Daiko, Hiroyuki
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 373 - 373
  • [28] Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma
    Huang, Bingjiang
    Shi, Haiyan
    Gong, Xiaohua
    Yu, Jing
    Xiao, Caixia
    Zhou, Bin
    Liang, Zibin
    Li, Xiaojian
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (05) : 2013 - 2021
  • [29] Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
    Yinfang Gu
    Xiaofang Zou
    Junlin Zhu
    Guowu Wu
    World Journal of Surgical Oncology, 23 (1)
  • [30] Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
    Zhao, Jian
    Lei, Junmei
    Yu, Junyan
    Zhang, Chengyan
    Song, Xuefeng
    Zhang, Ninggang
    Wang, Yusheng
    Zhang, Suxiang
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 500 - 506
12345